Cytosol‐Targeting Delivery of Non‐Nucleotide STING Agonist Achieves Inhalable Nanoparticle‐Based Anthrax Vaccine
Advanced Materials · 2026-05 · 38 (28)
DOI: 10.1002/adma.202512910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 20.04.2026. Verfasst von Xi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Shenyang, China. Hauptthemen laut MEDLINE: Anthrax Vaccines, Nanoparticles, Cytosol, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Inhalational anthrax is a deadly disease caused by inhalation of Bacillus anthracis spores. Current anthrax vaccines for human use have limitations including undefined components, limited mucosal immunity, and suboptimal adjuvant delivery. This study introduces 2 polymers, MP1 and MP2, each containing disulfide bonds. MP1 incorporates tertiary amines to induce proton sponge effect, while MP2 features terminal phenylboronic acid moieties for protein conjugation. Nanoparticle vaccine YM1.7 is created through self‐assembly of MP1, MP2, and STING agonist MSA‐2, followed by N─B coordination of recombinant protein antigen (rPA) on its surface. When administered via aerosolized intratracheal inoculation into the lung, YM1.7 is internalized by antigen‐presenting cell and trafficked to the lysosome, where acidic environment dissociates N─B bond, releasing rPA for antigen presentation. Proton sponge effect allows nanoparticle to escape into the cytosol, and then disulfide bond cleavage triggered by cytosolic glutathione causes dissociation of nanoparticle and release of MSA‐2 within the cytosol, significantly enhancing bioavailability of MSA‐2 as an adjuvant. This spatiotemporal delivery mechanism elicits a coordinated innate, humoral, mucosal, and cell‐mediated immune response in mice, providing strong protection against inhalational anthrax. Given its modular design nature, YM1.7 represents a promising platform for developing next‐generation mucosal vaccines against infections and cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Shenyang, China.
- State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
- Beijing National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China.
ORCID-Profile: Dongsheng Zhou
Förderung
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Zhang, X., Dai, C., Zhang, H., Wang, Y., Song, X., Fu, S., Li, Z., Xiao, H., Chen, Z., & Zhou, D. (2026). Cytosol‐Targeting Delivery of Non‐Nucleotide STING Agonist Achieves Inhalable Nanoparticle‐Based Anthrax Vaccine. Advanced Materials, 38(28). https://doi.org/10.1002/adma.202512910
Vancouver
Zhang X, Dai C, Zhang H, Wang Y, Song X, Fu S, et al. Cytosol‐Targeting Delivery of Non‐Nucleotide STING Agonist Achieves Inhalable Nanoparticle‐Based Anthrax Vaccine. Advanced Materials. 2026;38(28). doi:10.1002/adma.202512910
BibTeX
@article{Zhang2026,
author = {Zhang, Xi and Dai, Chenxi and Zhang, Hanchen and Wang, Yaling and Song, Xiaolin and Fu, Shengnan and Li, Zhixin and Xiao, Haihua and Chen, Zeliang and Zhou, Dongsheng},
title = {Cytosol‐Targeting Delivery of Non‐Nucleotide STING Agonist Achieves Inhalable Nanoparticle‐Based Anthrax Vaccine},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {28},
doi = {10.1002/adma.202512910}
}
EUVIMED